23:52 , Aug 8, 2019 |  BC Innovations  |  Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

Early clinical readouts for next-generation oncolytic viruses are hinting at high efficacy when combined with checkpoint inhibitors, and pharmas are off to the races to find the best pairings. After more than two decades of...
13:30 , Dec 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest an oncolytic herpes simplex virus (HSV) expressing CDH1 could help treat glioblastoma multiforme (GBM). An oncolytic HSV was engineered to express human CDH1 to enhance cell-to-cell transmission and reduce...
13:41 , Apr 13, 2018 |  BC Week In Review  |  Company News

Otsuka gets Japanese rights to Takara's TCR, CAR therapies

Takara Bio Inc. (Tokyo:4974) granted Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) exclusive co-development and Japanese commercialization rights to cancer candidates TBI-1301, a cancer/testis antigen 1B (NY-ESO-1; CTAG1B)-targeted short interfering T cell receptor therapy, and TBI-1501,...
22:49 , Apr 10, 2018 |  BC Extra  |  Company News

Otsuka gets Japanese rights to Takara's TCR, CAR therapies

Takara Bio Inc. (Tokyo:4974) granted Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) co-development and exclusive Japanese commercialization rights to cancer candidates TBI-1301, a cancer/testis antigen 1B (NY-ESO-1; CTAG1B)-targeted short interfering T cell receptor therapy, and TBI-1501,...
19:11 , Aug 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest mesenchymal stem cells (MSCs) loaded with oncolytic herpes simplex virus (HSV) could help treat the dispersed brain metastases of melanoma. In a human melanoma lymph node metastasis...
22:07 , Dec 30, 2016 |  BC Week In Review  |  Company News

Takara Bio, Otsuka deal

The companies partnered to co-develop Takara's HF10 oncolytic virus therapy in Japan to treat pancreatic, skin and other cancers. Otsuka will subsequently have exclusive rights to commercialize the mutant of herpes simplex virus type 1...
08:00 , Nov 20, 2008 |  BC Innovations  |  Tools & Techniques

Table 1. Oncolytic virus therapies

Table 1. Oncolytic virus therapies Table 1. Oncolytic virus therapies. At least 13 oncolytic virus therapies are in development for various cancers. Table 1. Oncolytic virus therapies. At least 13 oncolytic virus therapies are in...